We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
MINJUVI Specialised Therapeutics Alim Pty Ltd
Product name
MINJUVI
Accepted date
Apr-2025
Active ingredients
tafasitamab
Proposed indication
MINJUVI (tafasitamab), in combination with rituximab and lenalidomide, is an anticancer drug used to treat adult patients with previously treated follicular lymphoma (a cancer of the immune system).
Application type
C (new indication)
Publication date
Apr-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.